Get 20% Off Journals at LWW.com

Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.

Leuk Lymphoma 2018 07 13;59(7):1539-1553. Epub 2017 Sep 13.

a Center for Cellular Immunotherapies, Perelman School of Medicine , University of Pennsylvania , Philadelphia , PA , USA.

Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates of up to 90%. CART therapy has a unique toxicity profile, and unfortunately not all responses are durable. Treatment failure occurs via two main routes - by loss of the CART cell population, or relapse with antigen loss. Emerging data indicate that targeting an alternative antigen instead of, or as well as CD19, could improve CART cell efficacy and reduce antigen-negative relapse. Other strategies include the addition of other immune-based therapies. This review explores the rationale, pre-clinical data and currently investigative strategies underway for CART therapy targeting the myeloid and lymphoid stem/progenitor antigen CD123.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1375107DOI Listing
July 2018
Save 15% Survey

Similar Publications

Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.

Cancer Sci 2021 Jan 8. Epub 2021 Jan 8.

Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

In recent years, the excellent curative effect of CD19-specific chimeric antigen receptor (CAR) T-cell therapy has brought hope to patients with relapsing or refractory B-cell hematological malignancies, however relapse after CAR T-cell infusion has hindered the widespread clinical application of this immunotherapy and targeted antigen-negative relapse has caused widespread concern. Consequently, strategies for increasing targeted antigens have been created. In addition to the most widely applied target, namely CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T-cell therapies. Read More

View Article and Full-Text PDF
January 2021

A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.

Cancer Discov 2020 Dec 17. Epub 2020 Dec 17.

Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.

T cell-based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance mechanisms. We used a CRISPR/Cas9 screen and identified a necessary role for Fas-FasL in antigen-specific T-cell killing. Read More

View Article and Full-Text PDF
December 2020

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies.

Ther Adv Med Oncol 2020 13;12:1758835920962963. Epub 2020 Oct 13.

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Chimeric antigen receptor (CAR) T-cell therapy is a rapidly developing method for adoptive immunotherapy of tumours in recent years. CAR T-cell therapies have demonstrated unprecedented efficacy in the treatment of patients with haematological malignancies. A 90% complete response (CR) rate has been reported in patients with advanced relapse or refractory acute lymphoblastic leukaemia, while >50% CR rates have been reported in cases of chronic lymphocytic leukaemia and partial B-cell lymphoma. Read More

View Article and Full-Text PDF
October 2020

Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.

Expert Rev Clin Immunol 2020 10;16(10):1029-1042

Division of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania , Philadelphia, USA.

Introduction: Though 85% of children and young adults with acute lymphoblastic leukemia (ALL) are cured, until recently, the prognosis of relapsed or refractory disease has been dismal. The advent of chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory ALL. The most well-studied, successful CARs are autologous, murine-based anti-CD19 CARs, but new constructs are currently under clinical investigation. Read More

View Article and Full-Text PDF
October 2020

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.

Front Med 2020 Dec 13;14(6):726-745. Epub 2020 Aug 13.

Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.

Chimeric antigen receptor (CAR) T cells have been indicated effective in treating B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma and have shown encouraging results in preclinical and clinical studies. However, CAR T cells have achieved minimal success against solid malignancies because of the additional obstacles of their insufficient migration into tumors and poor amplification and persistence, in addition to antigen-negative relapse and an immunosuppressive microenvironment. Various preclinical studies are exploring strategies to overcome the above challenges. Read More

View Article and Full-Text PDF
December 2020